Author
@BioStocks BioStocks
grade Cx.com/BioStocks ↗
High-volume biotech catalyst news desk relaying FDA, trial, and pharma M&A flow
Aggregates and relays real-time biotech/pharma catalysts — F
trader score
-3.02
hit rate
25%
mean α
-2.87%
signals 14d
70
Grade = how their written analysis reads (A best). Trader score = how their last-20 timestamped calls performed vs SPY.
Their picks, scored
Across their last 20 scored bets: 25% hit rate, -2.87% mean alpha, trader score -3.02. Their last-14d mentions, direction-adjusted, have moved -2.0% since posting (mean over 33 mentions with price data).
Recent signals15receipts included
| date (PT) | ticker | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|---|
| 2026-08-28 | PTGX | @BioStocks | +0.50 | FDA approval triggers $275M milestones, 14%-29% royalties and up to $875M more | · | tweet ↗ |
| 2026-08-28 | KZIA | @BioStocks | -0.30 | Kazia prices a $120 million offering at $15.50 per ADS. | · | tweet ↗ |
| 2026-08-28 | LLY | @BioStocks | +0.50 | FDA approves Mounjaro to reduce cardiovascular risk in adults with type 2 diabetes. | — | tweet ↗ |
| 2026-08-28 | TEVA | @BioStocks | +0.05 | Teva could acquire worldwide asset rights for $57.5M upfront plus up to $67.5M contingent payments. | — | tweet ↗ |
| 2026-08-28 | TEVA | @BioStocks | +0.10 | BTAI files for bankruptcy and enters an asset-sale agreement with Teva. | — | tweet ↗ |
| 2026-08-28 | BTAI | @BioStocks | -0.75 | BTAI files for bankruptcy and enters an asset-sale agreement with Teva. | · | tweet ↗ |
| 2026-08-28 | QNRX | @BioStocks | -0.30 | Quoin announces a $50 million PIPE priced at $4.88 per ADS. | · | tweet ↗ |
| 2026-08-28 | QNRX | @BioStocks | +0.65 | QNRX reports statistically significant positive interim Phase 2/3 data in the first six patients. | · | tweet ↗ |
| 2026-08-27 | VRCA | @BioStocks | +0.30 | Reports completion of enrollment in the first pivotal Phase 3 COVE-2 trial with Q1 2027 data expected. | · | tweet ↗ |
| 2026-08-27 | CTMX | @BioStocks | +0.50 | Reports FDA Fast Track designation for varsetatug masetecan in metastatic colorectal cancer. | · | tweet ↗ |
| 2026-08-27 | NVDA | @BioStocks | +0.40 | Reports Raymond James raising Nvidia's price target to $515. | -4.6% | tweet ↗ |
| 2026-08-27 | AMGN | @BioStocks | +0.50 | Reports positive Phase 3 TEZSPIRE results across both co-primary and all key secondary endpoints. | -1.0% | tweet ↗ |
| 2026-08-27 | AZN | @BioStocks | +0.50 | Reports positive Phase 3 TEZSPIRE results across both co-primary and all key secondary endpoints. | -1.1% | tweet ↗ |
| 2026-08-27 | NVO | @BioStocks | -0.40 | Reports Deutsche Bank downgrading Novo Nordisk to Sell; LLY is merely a topic tag. | -1.4% | tweet ↗ |
| 2026-08-26 | RVMD | @BioStocks | +0.40 | Oppenheimer raises RVMD's price target to $260. | -3.5% | tweet ↗ |
Grade is our human read-worthiness rating; trader score is a rolling 20-bet hit-rate/alpha composite — different things, often disagreeing. “Since then” is direction-unaware in the table; the summary line above adjusts for which way they leaned.